In a patient with high risk acute promyelocytic leukemia, when do you consider ATRA+ATO with GO vs ATRA+ATO with idarubicin?

Given the recent publications with ATRA/ATO and GO in high risk patients or low risk patients who develop leukocytosis (Blood 2017) and the long term follow up of the comparative study form the NCRI AML Working Group (Blood 2018), GO is my preference in all cases unless there is hepatic toxicity or ...